Five Prime Therapeutics

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures.

CytomX Therapeutics

G1 Therapeutics

Mersana Therapeutics

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) has just concluded, and there were some significant moves we saw as a result.

ASCO Winners That Could Still More Than Double

Five Prime Therapeutics, Inc. (FPRX) CEO Aron Knickerbocker on Q1 2019 Results - Earnings Call Transcript

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates

Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Five Prime Therapeutics Stock (FPRX)